MarketBeat
07 Nov 2026, 05:15 UTC · 2h ago
Cardinal Health Q1 Earnings Call Highlights
Impact · against what's priced in
CAH is a moderate buy as the earnings raise and increased pharmaceutical profit growth provide concrete evidence for the bull case the market had previously rejected. CVS remains largely unchanged as the contract renewal with Cardinal Health was already anticipated and provides stability rather than new growth.
- CAH+0.50
Challenges what's priced in
- The price assumes
The Leerink Partners bull case for fiscal 2027 profits significantly above current Wall Street expectations
The market had rejected the bull case for higher 2027 profits, but the company just raised its non-GAAP EPS outlook to $12.80–$13.00 (up from $12.40–$12.60) and increased pharmaceutical profit growth forecasts to 10%–12%.
What CAH's price assumes · Sep 4
